MedTrace Logo

A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies

NCT02223598 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2018-02-27

No results posted yet for this study

Summary

The purpose of this study is to determine the safety, tolerability, dose limiting toxicities, and maximum tolerated dose of CB-5083 in subjects with lymphoid hematological malignancies.

Conditions

  • Lymphoid Hematological Malignancies
  • Relapsed and Refractory Multiple Myeloma

Interventions

DRUG

CB-5083

DRUG

Dexamethasone

Sponsors & Collaborators

  • Cleave Biosciences, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-25
Primary Completion
2017-07-26
Completion
2017-07-26

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02223598 on ClinicalTrials.gov